Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDG-PET lymphoma demonstration project invitational workshop.
Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J. Kelloff GJ, et al. Among authors: zelenetz ad. Acad Radiol. 2007 Mar;14(3):330-9. doi: 10.1016/j.acra.2006.12.003. Acad Radiol. 2007. PMID: 17307666
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. O'Connor OA, et al. Among authors: zelenetz ad. J Clin Oncol. 2005 Feb 1;23(4):676-84. doi: 10.1200/JCO.2005.02.050. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613699 Clinical Trial.
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL. Bennett JM, et al. Among authors: zelenetz ad. Blood. 2005 Jun 15;105(12):4576-82. doi: 10.1182/blood-2004-12-4690. Epub 2005 Feb 24. Blood. 2005. PMID: 15731177 Free article.
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH. Hamlin PA, et al. Among authors: zelenetz ad. Br J Haematol. 2005 Sep;130(5):691-9. doi: 10.1111/j.1365-2141.2005.05661.x. Br J Haematol. 2005. PMID: 16115124 Free article.
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. Fisher RI, et al. Among authors: zelenetz ad. J Clin Oncol. 2005 Oct 20;23(30):7565-73. doi: 10.1200/JCO.2004.00.9217. Epub 2005 Sep 26. J Clin Oncol. 2005. PMID: 16186600 Clinical Trial.
319 results